Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nóra Kucsápszky has a total of 30 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Lab-on-a-chip device integrating a human stem cell-based blood-brain barrier model with neural organoids for translational research

    by Judit P. Vigh, Anna E. Kocsis, Ana Raquel Santa-Maria, Nora Kucsapszky, Emese Bato, Silvia Bolognin, Jens Christian Schwamborn, Andras Kincses, Sandor Valkai, Aniko Szecsko, et al.

    For advanced biomedical research, complex, well-described human blood-brain barrier (BBB) models are crucial for studying central nervous system pathologies and brain targeting of nanotherapeutics. Our aim was to establish and characterize a complex lab-on-a-chip (LOC) system integrating a BBB model with neural organoids (NO). We optimized the conditions for BBB-NO models under static and dynamic circumstances. The combination of a human stem cell-derived BBB co-culture model with human midbrain organoids in a microfluidic LOC allowed the observation of BBB and neural tissue changes and the separate analysis of the barrier and brain units. The LOC design enabled phase contrast and fluorescent microscopy on the whole brain endothelial culture surface, barrier integrity and permeability measurements across the BBB model, and molecule passage into NOs. BBB-specific endothelial morphology, gene and protein expression, and good barrier integrity were demonstrated, corroborating the strength of the LOC engineering and cellular design. The transport of targeted nanoparticles across the BBB model followed by their entry to neural organoids validated the barrier integrity and transporter functionality of the dynamic integrated complex model. As a proof-of-concept experiment to confirm the translational value of the BBB-NO model integrated in the LOC device, we examined a clinically used hyperosmolar iodinated contrast agent, iopamidol, with confirmed neurological side effects. We corroborated that iopamidol induces transient BBB dysfunction and neural effects in the complex system, not only validating the complex dynamic BBB-NO model but also pointing to the necessity to study BBB changes together with NO functions.

  • In vitro blood-brain barrier models for the study of brain shuttle peptide transport

    by Ana Martins, Ana Raquel Santa-Maria, Nóra Kucsápszky, Luíza Santa Brígida de Barros Góes, Kinga Molnár, Sheila Sousa Gomes Fortes, Emanuel Carrilho, Maria A. Deli, Fruzsina R. Walter

  • Open Access

    Much More than Nutrients: The Protective Effects of Nutraceuticals on the Blood–Brain Barrier in Diseases

    by Anna E. Kocsis, Nóra Kucsápszky, Ana Raquel Santa-Maria, Attila Hunyadi, Mária A. Deli, Fruzsina R. Walter

    The dysfunction of the blood–brain barrier (BBB) is well described in several diseases, and is considered a pathological factor in many neurological disorders. This review summarizes the most important groups of natural compounds, including alkaloids, flavonoids, anthocyanidines, carotenoids, lipids, and vitamins that were investigated for their potential protective effects on brain endothelium. The brain penetration of these compounds and their interaction with BBB efflux transporters and solute carriers are discussed. The cerebrovascular endothelium is considered a therapeutic target for natural compounds in diseases. In preclinical studies modeling systemic and central nervous system diseases, nutraceuticals exerted beneficial effects on the BBB. In vivo, they decreased BBB permeability, brain edema, astrocyte swelling, and morphological changes in the vessel structure and basal lamina. At the level of brain endothelial cells, nutraceuticals increased cell survival and decreased apoptosis. From the general endothelial functions, decreased angiogenesis and increased levels of vasodilating agents were demonstrated. From the BBB functions, elevated barrier integrity by tightened intercellular junctions, and increased expression and activity of BBB transporters, such as efflux pumps, solute carriers, and metabolic enzymes, were shown. Nutraceuticals enhanced the antioxidative defense and exerted anti-inflammatory effects at the BBB. The most important signaling changes mediating the increased cell survival and BBB stability were the activation of the WNT, PI3K-AKT, and NRF2 pathways, and inhibition of the MAPK, JNK, ERK, and NF-κB pathways. Nutraceuticals represent a valuable source of new potentially therapeutic molecules to treat brain diseases by protecting the BBB.